JP2019518733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518733A5 JP2019518733A5 JP2018558750A JP2018558750A JP2019518733A5 JP 2019518733 A5 JP2019518733 A5 JP 2019518733A5 JP 2018558750 A JP2018558750 A JP 2018558750A JP 2018558750 A JP2018558750 A JP 2018558750A JP 2019518733 A5 JP2019518733 A5 JP 2019518733A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- glycopeptide antibiotic
- composition according
- sulfobutyl ether
- beta cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 24
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 13
- 235000001014 amino acid Nutrition 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- KTHDTJVBEPMMGL-GSVOUGTGSA-N n-acetylalanine Chemical compound OC(=O)[C@@H](C)NC(C)=O KTHDTJVBEPMMGL-GSVOUGTGSA-N 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 claims 2
- 108010053950 Teicoplanin Proteins 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 2
- 229960002488 dalbavancin Drugs 0.000 claims 2
- 108700009376 dalbavancin Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 229960001607 oritavancin Drugs 0.000 claims 2
- 108010006945 oritavancin Proteins 0.000 claims 2
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims 2
- 229960001608 teicoplanin Drugs 0.000 claims 2
- 229960005240 telavancin Drugs 0.000 claims 2
- 108010089019 telavancin Proteins 0.000 claims 2
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims 2
- 229960003165 vancomycin Drugs 0.000 claims 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 claims 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 1
- 229930195711 D-Serine Natural products 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 1
- 229930182819 D-leucine Natural products 0.000 claims 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 1
- 229930182831 D-valine Natural products 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333357P | 2016-05-09 | 2016-05-09 | |
| US62/333,357 | 2016-05-09 | ||
| PCT/EP2017/060653 WO2017194385A1 (en) | 2016-05-09 | 2017-05-04 | Stabilized glycopeptide antibiotic formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518733A JP2019518733A (ja) | 2019-07-04 |
| JP2019518733A5 true JP2019518733A5 (enExample) | 2020-06-18 |
| JP6946343B2 JP6946343B2 (ja) | 2021-10-06 |
Family
ID=58745200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558750A Active JP6946343B2 (ja) | 2016-05-09 | 2017-05-04 | 安定化されたグリコペプチド抗生物質製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10729708B2 (enExample) |
| EP (1) | EP3454883A1 (enExample) |
| JP (1) | JP6946343B2 (enExample) |
| KR (1) | KR20190005940A (enExample) |
| CN (1) | CN109069580A (enExample) |
| AR (1) | AR109454A1 (enExample) |
| AU (1) | AU2017262943B2 (enExample) |
| BR (1) | BR112018072948A2 (enExample) |
| CL (1) | CL2018003147A1 (enExample) |
| CO (1) | CO2018011701A2 (enExample) |
| EA (1) | EA201892413A1 (enExample) |
| IL (1) | IL262796A (enExample) |
| JO (2) | JOP20170111B1 (enExample) |
| MX (1) | MX388732B (enExample) |
| SA (1) | SA518400392B1 (enExample) |
| SG (1) | SG11201809908TA (enExample) |
| TW (2) | TWI772296B (enExample) |
| UY (1) | UY37233A (enExample) |
| WO (1) | WO2017194385A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102603756B1 (ko) | 2014-11-06 | 2023-11-16 | 셀리아 파마슈티칼즈 에이피에스 | 글리코펩티드 조성물 |
| WO2021231361A1 (en) * | 2020-05-11 | 2021-11-18 | Anovent Pharmaceutical (U.S.), Llc | Pharmaceutical formulation containing active metabolites of remdesivir for inhalation |
| EP4192247A4 (en) * | 2020-08-04 | 2025-01-08 | Harrow IP, LLC | Antibacterial compositions and methods for fabricating thereof |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| CN115804832A (zh) * | 2021-09-14 | 2023-03-17 | 海南普利制药股份有限公司 | 一种万古霉素水溶液组合物 |
| WO2023171588A1 (ja) * | 2022-03-08 | 2023-09-14 | 国立大学法人大阪大学 | 抗菌薬を含有するｐｌｇａ製剤 |
| WO2023211501A1 (en) * | 2022-04-26 | 2023-11-02 | Hikma Pharmaceuticals Usa Inc. | Stable, ready-to-administer aqueous formulations of dalbavancin |
| GB202207344D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
| GB202207345D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
| CN117618338A (zh) * | 2022-08-16 | 2024-03-01 | 海南普利制药股份有限公司 | 一种稳定的奥利万星药物水溶液及其制备方法 |
| WO2024079223A1 (en) * | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
| UY40481A (es) * | 2022-10-12 | 2024-04-30 | Hikma Pharmaceuticals Usa Inc | Composición líquida de dalbavancina |
| EP4431083A1 (en) * | 2023-03-16 | 2024-09-18 | Adalvo Limited | Formulation of dalbavancin |
| WO2025158262A1 (en) * | 2024-01-23 | 2025-07-31 | Lupin Limited | Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1278549A (en) * | 1916-12-16 | 1918-09-10 | J E Simmons | Nut and bolt lock. |
| US4670258A (en) | 1984-02-10 | 1987-06-02 | Vanderbilt University | Storable prepackaged aqueous solutions of vancomycin |
| US4885275A (en) | 1987-10-15 | 1989-12-05 | Eli Lilly And Company | Vancomycin-HCL solutions and the lyophilization thereof |
| AU1407197A (en) * | 1995-12-01 | 1997-06-19 | Eli Lilly And Company | Stable vancomycin hydrochloride solutions |
| JPH1180021A (ja) | 1997-09-02 | 1999-03-23 | Kayaku:Kk | バンコマイシン注射剤 |
| EP1278549B1 (en) * | 2000-05-02 | 2008-12-10 | Theravance, Inc. | Composition containing a cyclodextrin and a glycopeptide antibiotic |
| SI1276759T1 (sl) * | 2000-05-02 | 2008-12-31 | Theravance Inc | Postopek reduktivnega alkiliranja na glikopeptidih |
| WO2001083520A2 (en) * | 2000-05-02 | 2001-11-08 | Theravance,Inc | Polyacid glycopeptide derivatives |
| CA2413251C (en) * | 2000-06-21 | 2012-06-12 | Cubist Pharmaceuticals, Inc. | Compositions and methods to improve the oral absorption of antimicrobial agents |
| UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US7119061B2 (en) * | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
| WO2005042584A2 (en) * | 2003-10-31 | 2005-05-12 | The University Of Kansas | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives |
| PT1848413E (pt) | 2005-02-14 | 2014-07-18 | Venus Remedies Ltd | Terapia de combinação parentérica para afecções infecciosas com bactérias resistentes a fármacos |
| CN1857716A (zh) * | 2006-03-14 | 2006-11-08 | 浙江大学 | 注射用盐酸万古霉素及其制备方法 |
| JP2008201778A (ja) | 2007-01-25 | 2008-09-04 | Mochida Pharmaceut Co Ltd | バンコマイシン液状製剤 |
| EA017564B1 (ru) | 2007-09-12 | 2013-01-30 | Тарганта Терапьютикс Корп. | Способ ингибирования клостридиум диффициле введением оритаванцина |
| US7635773B2 (en) * | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| CN102755629A (zh) * | 2012-08-02 | 2012-10-31 | 上海瑞创医药科技有限公司 | 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用 |
| MX2015006681A (es) | 2012-11-29 | 2016-04-06 | Insmed Inc | Formulaciones de vancomicina estabilizadas. |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| US9616098B2 (en) | 2013-05-30 | 2017-04-11 | Scidose, Llc | Formulations of vancomycin |
| KR102603756B1 (ko) * | 2014-11-06 | 2023-11-16 | 셀리아 파마슈티칼즈 에이피에스 | 글리코펩티드 조성물 |
| EA036750B1 (ru) | 2016-01-08 | 2020-12-16 | Гуфик Байосайенсиз Лимитед | Лиофилизированная парентеральная композиция тигециклина и способ ее приготовления |
| AU2017221435A1 (en) * | 2016-02-18 | 2018-09-06 | Melinta Therapeutics, Inc. | Oritavancin formulations |
-
2017
- 2017-05-04 EP EP17724773.1A patent/EP3454883A1/en not_active Withdrawn
- 2017-05-04 SG SG11201809908TA patent/SG11201809908TA/en unknown
- 2017-05-04 EA EA201892413A patent/EA201892413A1/ru unknown
- 2017-05-04 US US16/300,137 patent/US10729708B2/en active Active
- 2017-05-04 AU AU2017262943A patent/AU2017262943B2/en not_active Ceased
- 2017-05-04 WO PCT/EP2017/060653 patent/WO2017194385A1/en not_active Ceased
- 2017-05-04 BR BR112018072948-5A patent/BR112018072948A2/pt not_active IP Right Cessation
- 2017-05-04 JP JP2018558750A patent/JP6946343B2/ja active Active
- 2017-05-04 CN CN201780027315.7A patent/CN109069580A/zh active Pending
- 2017-05-04 KR KR1020187035449A patent/KR20190005940A/ko not_active Ceased
- 2017-05-04 MX MX2018013584A patent/MX388732B/es unknown
- 2017-05-07 JO JOJO/P/2017/0111A patent/JOP20170111B1/ar active
- 2017-05-08 UY UY0001037233A patent/UY37233A/es active IP Right Grant
- 2017-05-08 AR ARP170101197A patent/AR109454A1/es unknown
- 2017-05-09 TW TW106115255A patent/TWI772296B/zh active
- 2017-05-09 TW TW110104598A patent/TWI769694B/zh active
-
2018
- 2018-10-29 CO CONC2018/0011701A patent/CO2018011701A2/es unknown
- 2018-11-05 IL IL262796A patent/IL262796A/en unknown
- 2018-11-06 CL CL2018003147A patent/CL2018003147A1/es unknown
- 2018-11-07 SA SA518400392A patent/SA518400392B1/ar unknown
-
2022
- 2022-02-17 JO JOP/2022/0039A patent/JOP20220039A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533218A5 (enExample) | ||
| HRP20210342T1 (hr) | Pripravci glikopeptida | |
| CY1123242T1 (el) | Λυοφιλοποιημενο παρασκευασμα κυτταροτοξικων διπεπτιδιων | |
| Howe et al. | Self-assembled sorbitol-derived supramolecular hydrogels for the controlled encapsulation and release of active pharmaceutical ingredients | |
| Cacciatore et al. | Carvacrol codrugs: a new approach in the antimicrobial plan | |
| WO2013090861A8 (en) | Alpha-aminoamidine polymers and uses thereof | |
| AU2019376660A8 (en) | 2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities | |
| US20150175717A1 (en) | Hyaluronic Acid Derivative, Method of Preparation Thereof, Method of Modification Thereof and Use Thereof | |
| CY1118243T1 (el) | Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα | |
| BR112015023168A2 (pt) | composições de dicetopiperazina microcristalina e métodos | |
| Monaim et al. | Re-evaluation of the N-terminal substitution and the D-residues of teixobactin | |
| MX353900B (es) | Lipidoides de aminoalcohol y usos de los mismos. | |
| CN108178780B (zh) | 一种短肽修饰单宁酸纳米抗菌剂及其制备方法 | |
| JP2017061474A5 (enExample) | ||
| EP4684797A3 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| PH12021500011A1 (en) | Anti-cd137 antigen-binding molecule and utilization thereof | |
| WO2007135196A3 (en) | Stable soluble salts of phenylbenzimidazole sulfonic acid at phs at or below 7.0 | |
| WO2019090148A3 (en) | Compositions and methods related to therapeutic cell systems for tumor growth inhibition | |
| CY1112353T1 (el) | Παραγωγα μεταστινης και χρηση αυτων | |
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
| WO2017141204A3 (en) | Biguanide grafted / modified biopolymers as drug delivery vehicles | |
| WO2015173427A4 (fr) | Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique | |
| RU2015140720A (ru) | Некодирующий иммуномодулирующей конструкт днк с ковалентно закрытой структурой | |
| Lin et al. | Antimicrobial peptide-inspired antibacterial polymeric materials for biosafety | |
| JP2014530882A5 (enExample) |